These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 28452151

  • 1. PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A.
    Lissitchkov T, Rusen L, Georgiev P, Windyga J, Klamroth R, Gercheva L, Nemes L, Tiede A, Bichler J, Knaub S, Belyanskaya L, Walter O, Pasi KJ.
    Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
    Tiede A, Oldenburg J, Lissitchkov T, Knaub S, Bichler J, Manco-Johnson MJ.
    Haemophilia; 2016 May; 22(3):374-80. PubMed ID: 26582282
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of Nuwiq® (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures.
    Zozulya N, Kessler CM, Klukowska A, von Depka M, Hampton K, Hay CRM, Jansen M, Bichler J, Knaub S, Rangarajan S.
    Haemophilia; 2018 Jan; 24(1):70-76. PubMed ID: 29048712
    [Abstract] [Full Text] [Related]

  • 6. Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.
    Kessler C, Oldenburg J, Ettingshausen CE, Tiede A, Khair K, Négrier C, Klamroth R.
    Haemophilia; 2015 Jan; 21 Suppl 1():1-12. PubMed ID: 25472812
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P, Mullins ES, Konkle BA, McGuinn C, Park YS, Stasyshyn O, Zulfikar B, Engl W, Tangada S.
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A, Moonla C, Sosothikul D.
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
    Giangrande P, Andreeva T, Chowdary P, Ehrenforth S, Hanabusa H, Leebeek FW, Lentz SR, Nemes L, Poulsen LH, Santagostino E, You CW, Clausen WH, Jönsson PG, Oldenburg J, Pathfinder™2 Investigators.
    Thromb Haemost; 2017 Jan 26; 117(2):252-261. PubMed ID: 27904904
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A new paradigm for personalized prophylaxis for patients with severe haemophilia A.
    Delavenne X, Ollier E, Lienhart A, Dargaud Y.
    Haemophilia; 2020 Mar 26; 26(2):228-235. PubMed ID: 32100950
    [Abstract] [Full Text] [Related]

  • 18. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
    Mullins ES, Stasyshyn O, Alvarez-Román MT, Osman D, Liesner R, Engl W, Sharkhawy M, Abbuehl BE.
    Haemophilia; 2017 Mar 26; 23(2):238-246. PubMed ID: 27891721
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
    Kessler CM, Corrales-Medina FF, Mannucci PM, Jiménez-Yuste V, Tarantino MD.
    Eur J Haematol; 2023 Nov 26; 111(5):757-767. PubMed ID: 37587687
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.